All News

22 July 2008

Dyax Corp. and AVEO Pharmaceuticals Announce Antibody Library License AgreementAntibodies

22 July 2008

Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple SclerosisAntibodies

21 July 2008

Goodwin Biotechnology’s Manufactured Melanin-Binding Antibody Used in Successful Melanoma TrialAntibodies

19 July 2008

The Multiple Myeloma Research Consortium (MMRC) Announces the Initiation of Phase I/II Study of Elotuzumab (Huluc63) Monoclonal Antibody in Combination with VelcadeAntibodies

17 July 2008

Bradmer Reports Progression Free Survial Data from Previous Phase II Glioblastoma Multiforme TrialsAntibodies

17 July 2008

MediGene exercises option for Anti-L1 Monoclonal Antibody and continues collaboration with DKFZ (German Cancer Research Center)Antibodies

16 July 2008

Symphogen and Biovitrum have Initiated a Novel Treatment Study in Autoimmune Bleeding Disorder (ITP) PatientsAntibodies

16 July 2008

Merck: Erbitux Approved for Use in Metastatic Colorectal Cancer in JapanAntibodies

16 July 2008

BioWa and Medarex Announce License of BioWa’s COMPLEGENT(TM) TechnologyAntibodies

15 July 2008

Lonza and Kyowa Hakko extend their strategic collaborationAntibodies

14 July 2008

MRC Technology and Biolex Therapeutics Successfully Complete Collaboration to Humanize a Novel Antibody Targeting CD20Antibodies

14 July 2008

Nycomed adds veltuzumab for autoimmune diseases to R&D pipelineAntibodies

14 July 2008

Amgen Announces Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation TherapyAntibodies

10 July 2008

Recruitment Completed in Ofatumumab CLL Front Line StudyAntibodies

9 July 2008

Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (basiliximab) for Noninfectious UveitisAntibodies

9 July 2008

Merck Begins Erbitux Phase III Clinical Study in Gastric CancerAntibodies

9 July 2008

Boehringer Ingelheim Gains Access to Additional MorphoSys TechnologyAntibodies

8 July 2008

Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Daiichi SankyoAntibodies

7 July 2008

Phase 2 Study Of IMC-A12 for Advanced Soft Tissue Sarcoma Opens for Patient EnrollmentAntibodies

7 July 2008

ImmunoGen, Inc. Announces Start of IMGN388 Clinical TestingAntibodies

3 July 2008

Phase III ARISER study with RENCAREX(R): patient recruitment successfully completedAntibodies

2 July 2008

Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast CancerAntibodies

1 July 2008

UCB’s Cimzia(R) filed with EMEA for treatment of rheumatoid arthritisAntibodies

30 June 2008

Takeda Submitted a New Drug Application for Anti-Cancer Agent, panitumumab (recombinant)Antibodies

29 June 2008

Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisAntibodies

29 June 2008

New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix(R) (Panitumumab)Antibodies

25 June 2008

Genmab Initiates Study of Zalutumumab with Radiotherapy in Head and Neck CancerAntibodies

25 June 2008

CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast CancerAntibodies

25 June 2008

IMC-A12 Plus Temsirolimus Clinical Trial for Advanced Cancer Opens for Patient EnrollmentAntibodies

24 June 2008

Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune DiseasesAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

PSMA-Targeted Therapy Pipeline Review

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

FcRn Inhibitors Pipeline Review

CD40 Agonists & CD40/L Antagonists Pipeline Review

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount